Overexpression of fibroblast growth factor receptors FGFR1 and FGFR2 in renal cell carcinoma
- 18 February 2011
- journal article
- Published by Taylor & Francis Ltd in Scandinavian Journal of Urology and Nephrology
- Vol. 45 (3), 190-195
- https://doi.org/10.3109/00365599.2011.552436
Abstract
Fibroblast growth factor/fibroblast growth factor receptor (FGF/FGFR) has recently emerged as a critical event in the transformation and tumorigenicity of several murine and human tumors. This pathway could be a mechanism driving angiogenesis in patients with metastatic renal cell carcinoma (RCC). Membrane antigens such as FGFR expressed in RCC are attractive targets for new therapeutic and diagnostic applications. This study evaluated the expression of FGFR1 and FGFR2 in RCC. Formalin-fixed, paraffin-embedded specimens of 100 primary tumors and 40 metastatic lymph nodes removed from 140 untreated RCC patients were evaluated by immunohistochemistry with FGFR1 and FGFR2 antibodies. The extent of FGFR expression was compared with 40 specimens of normal human kidney tissue (selected from the surgical diagnostic files). Significant differences in the immunoexpression of FGFR among these groups were assessed bychi-squared and Fisher's exact tests using a semi-quantitative scoring system on the extent of stained cells and intensity of corresponding immunostained cells (0 to 3+). Expression of FGFR1 was observed in 98% (98/100) of primary renal tumors and in 82.5% (33/40) of lymph-node metastases. Intensity was 3+ in allcases. Nuclear expression of FGFR1 was found in 68% (95/140). FGFR2 staining was seen in 4% (4/100) of primary tumors and in 5% (2/40) of lymph-node metastases. FGFR2 was expressed in RCC of non-clear cell histology. FGFR1 expression was significantly lower in the normal kidney tissue(p = 0.001) and was detected in 2.5% of cases (1/40); no FGFR2 expression was found. This study has shown for the first time that FGFR1 is highly expressed in RCC patients.Keywords
This publication has 14 references indexed in Scilit:
- Resistance to targeted therapy in renal-cell carcinomaThe Lancet Oncology, 2009
- Targeted therapies in metastatic renal cancer in 2009BJU International, 2009
- The discovery of basic fibroblast growth factor/fibroblast growth factor-2 and its role in haematological malignanciesCytokine & Growth Factor Reviews, 2007
- Correlation of bFGF expression in renal cell cancer with clinical and histopathological features by tissue microarray analysis and measurement of serum levelsZeitschrift für Krebsforschung und Klinische Onkologie, 2005
- Structural basis for fibroblast growth factor receptor activationCytokine & Growth Factor Reviews, 2005
- Mechanisms underlying differential responses to FGF signalingCytokine & Growth Factor Reviews, 2005
- Fibroblast Growth Factors and Their Receptors in Urological Cancers: Basic Research and Clinical ImplicationsEuropean Urology, 2003
- Renal cancer: molecular mechanisms and newer therapeutic optionsCurrent Opinion in Nephrology and Hypertension, 2002
- Clinical Implications of Circulating Angiogenic Factors in Cancer PatientsJournal of Clinical Oncology, 2001
- Fibroblast growth factorsGenome Biology, 2001